Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High Dose Simplified FOLFIRI
- Development stage
- Unknown
- Lead developer
- Ghent University Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
High Dose Simplified FOLFIRI is a combination chemotherapy regimen consisting of leucovorin (folinic acid), fluorouracil (5-FU), and irinotecan. This specific variant is being investigated by the University Hospital, Ghent, as a first-line treatment for patients with advanced colorectal cancer in a multicentre phase II study. The regimen works through multiple mechanisms: irinotecan is a small molecule topoisomerase I inhibitor that prevents DNA replication by stabilizing the cleavable complex between the enzyme and DNA, leading to double-strand breaks; fluorouracil is an antimetabolite that is converted into active metabolites which inhibit thymidylate synthase, thereby interfering with DNA synthesis; and leucovorin (folinic acid) acts as a biochemical modulator that increases the intracellular pool of reduced folates, stabilizing the binding of fluorouracil's active metabolite to thymidylate synthase and significantly enhancing its cytotoxic activity.
- Other names
- FOLFIRIleucovorin + fluorouracil + irinotecanHigh Dose Simplified Folfiri
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on High Dose Simplified FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on High Dose Simplified FOLFIRI.